TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02453360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
Study: NCT03321734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
Study: NCT05051137

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.

Intervention type: DRUG
Intervention: Sulfasalazine + Hydroxychloroquine
Description: Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
Study: NCT04071353

Intervention type: DRUG
Intervention: Interferon
Description: Interferon combined with ribavirin antiviral therapy

Intervention type: DRUG
Intervention: ribavirin
Description: Interferon combined with ribavirin antiviral therapy

Intervention type: DRUG
Intervention: DAAs
Description: DAAs antiviral treatment
Study: NCT00261001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transcutaneous mode of administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular mode of administration
Study: NCT04581616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathoracic Intercostal Nerve Block
Description: Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
Study: NCT00642551

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: 180 µg menaquinone-7 daily for three years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo capsule daily for three years
Study: NCT02600455

Intervention type: DRUG
Intervention: Orencia
Study: NCT00629655

Intervention type: OTHER
Intervention: motor task, sensory stimulation
Description: motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation

Intervention type: OTHER
Intervention: motor task, sensory stimulation
Description: motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation
Study: NCT03299751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diagnostic performances of biomarkers combination
Description: A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.
Study: NCT04318951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive communicative-pragmatic social interaction.
Description: ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[...\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care.
Description: Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care.
Description: Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
Study: NCT02545322

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Follow-up CT scans during week 3 and week 5 of treatment
Description: Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
Study: NCT04162223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat injection of Recombivax-HB
Description: Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of Recombivax-HB
Description: Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
Study: NCT03208322

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02583035

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse telephone contact
Description: Nurse will contact patient 3 days before consultation
Study: NCT00298909

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: physical exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niaspan (extended-release niacin)
Description: niaspan (extended-release niacin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin
Description: niacin extended-release

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control
Study: NCT04051788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step Aerobics
Description: Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise (Lower limb Cycling)
Description: Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
Study: NCT01215500

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Description: RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy
Study: NCT04260009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib AAF
Description: Brigatinib age-appropriate formulation (AAF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib AAF
Description: Brigatinib age-appropriate formulation (AAF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib AAF
Description: Brigatinib age-appropriate formulation (AAF)
Study: NCT03318809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986
Description: tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 986
Description: tablets for oral administration
Study: NCT03525990

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
Study: NCT00307125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus immunosuppression
Description: Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus immunosuppression
Description: Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific.
Study: NCT02007889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: 50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
Study: NCT03837379

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Goal2Quit + NRT Sampling
Description: Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study: NCT01134016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded.
Study: NCT03545009

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrate
Description: 70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice no Nitrate
Description: 70ml Concentrated Beetroot Juice with nitrate removed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice
Description: 70ml Concentrated Beetroot Juice
Study: NCT00934141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
Study: NCT00529022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg by mouth Daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein on Days 3 and 10 over 60 Minutes.
Study: NCT01106404

Intervention type: DEVICE
Group type: OTHER
Intervention: RestoreSensor Neurostimulation System
Description: Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF.

Intervention type: DEVICE
Group type: OTHER
Intervention: RestoreSensor Neurostimulation System
Description: Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF.
Study: NCT00639561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g of fibres per day
Description: 10 g of fibres per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g of fibres per day
Description: 40g of fibres per day
Study: NCT03580772

Intervention type: DEVICE
Intervention: Persona TKR
Description: Persona® TKR (Zimmer Biomet)

Intervention type: DEVICE
Intervention: Attune TKR
Description: Attune® TKR (Depuy synthes)
Study: NCT02080455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg
Study: NCT02389114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
Study: NCT04005417

Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice

Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing potassium nitrate or arginine.

Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)